Q Z Lin, H Z Liu, W P Zhou, Z J Cheng, J Y Lou, S G Zheng, X Y Bi, J M Wang, W Guo, F Y Li, J Wang, Y M Zheng, J D Li, S Cheng, Y Y Zeng
{"title":"[术后辅助化疗对肝内胆管癌患者预后的影响:一项多中心回顾性研究]。","authors":"Q Z Lin, H Z Liu, W P Zhou, Z J Cheng, J Y Lou, S G Zheng, X Y Bi, J M Wang, W Guo, F Y Li, J Wang, Y M Zheng, J D Li, S Cheng, Y Y Zeng","doi":"10.3760/cma.j.cn112139-20230106-00010","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objectives:</b> To examine the influence of adjuvant chemotherapy after radical resection on the survival of patients with intrahepatic cholangiocarcinoma(ICC) and to identify patients who may benefit from it. <b>Methods:</b> The clinical and pathological data of 654 patients with ICC diagnosed by postoperative pathology from December 2011 to December 2017 at 13 hospitals in China were collected retrospectively. According to the inclusion and exclusion criteria,455 patients were included in this study,including 69 patients (15.2%) who received adjuvant chemotherapy and 386 patients (84.8%) who did not receive adjuvant chemotherapy. There were 278 males and 177 females,with age of 59 (16) years (<i>M</i>(IQR))(range:23 to 88 years). Propensity score matching (PSM) method was used to balance the difference between adjuvant chemotherapy group and non-adjuvant chemotherapy group. Kaplan-Meier method was used to plot the survival curve,the Log-rank test was used to compare the difference of overall survival(OS) and recurrence free survival(RFS)between the two groups. Univariate analysis was used to determine prognostic factors for OS. Multivariate Cox proportional hazards models were then performed for prognostic factors with <i>P</i><0.10 to identify potential independent risk factors. The study population were stratified by included study variables and the AJCC staging system,and a subgroup analysis was performed using the Kaplan-Meier method to explore the potential benefit subgroup population of adjuvant chemotherapy. <b>Results:</b> After 1∶1 PSM matching,69 patients were obtained in each group. There was no significant difference in baseline data between the two groups (all <i>P</i>>0.05). After PSM,Cox multivariate analysis showed that lymph node metastasis (<i>HR</i>=3.06,95%<i>CI</i>:1.52 to 6.16,<i>P</i>=0.039),width of resection margin (<i>HR</i>=0.56,95%<i>CI</i>:0.32 to 0.99,<i>P</i>=0.044) and adjuvant chemotherapy (<i>HR</i>=0.51,95%<i>CI</i>:0.29 to 0.91,<i>P</i>=0.022) were independent prognostic factors for OS. Kaplan-Meier analysis showed that the median OS time of adjuvant chemotherapy group was significantly longer than that of non-adjuvant chemotherapy group (<i>P</i><0.05). There was no significant difference in RFS time between the adjuvant chemotherapy group and the non-adjuvant chemotherapy group (<i>P</i>>0.05). Subgroup analysis showed that,the OS of female patients,without HBV infection,carcinoembryonic antigen<9.6 μg/L,CA19-9≥200 U/ml,intraoperative bleeding<400 ml,tumor diameter>5 cm,microvascular invasion negative,without lymph node metastasis,and AJCC stage Ⅲ patients could benefit from adjuvant chemotherapy (all <i>P</i><0.05). <b>Conclusion:</b> Adjuvant chemotherapy can prolong the OS of patients with ICC after radical resection,and patients with tumor diameter>5 cm,without lymph node metastasis,AJCC stage Ⅲ,and microvascular invasion negative are more likely to benefit from adjuvant chemotherapy.</p>","PeriodicalId":23966,"journal":{"name":"Zhonghua wai ke za zhi [Chinese journal of surgery]","volume":"61 4","pages":"305-312"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Effect of postoperative adjuvant chemotherapy on prognosis of patients with intrahepatic cholangiocarcinoma:a multicenter retrospective study].\",\"authors\":\"Q Z Lin, H Z Liu, W P Zhou, Z J Cheng, J Y Lou, S G Zheng, X Y Bi, J M Wang, W Guo, F Y Li, J Wang, Y M Zheng, J D Li, S Cheng, Y Y Zeng\",\"doi\":\"10.3760/cma.j.cn112139-20230106-00010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objectives:</b> To examine the influence of adjuvant chemotherapy after radical resection on the survival of patients with intrahepatic cholangiocarcinoma(ICC) and to identify patients who may benefit from it. <b>Methods:</b> The clinical and pathological data of 654 patients with ICC diagnosed by postoperative pathology from December 2011 to December 2017 at 13 hospitals in China were collected retrospectively. According to the inclusion and exclusion criteria,455 patients were included in this study,including 69 patients (15.2%) who received adjuvant chemotherapy and 386 patients (84.8%) who did not receive adjuvant chemotherapy. There were 278 males and 177 females,with age of 59 (16) years (<i>M</i>(IQR))(range:23 to 88 years). Propensity score matching (PSM) method was used to balance the difference between adjuvant chemotherapy group and non-adjuvant chemotherapy group. Kaplan-Meier method was used to plot the survival curve,the Log-rank test was used to compare the difference of overall survival(OS) and recurrence free survival(RFS)between the two groups. Univariate analysis was used to determine prognostic factors for OS. Multivariate Cox proportional hazards models were then performed for prognostic factors with <i>P</i><0.10 to identify potential independent risk factors. The study population were stratified by included study variables and the AJCC staging system,and a subgroup analysis was performed using the Kaplan-Meier method to explore the potential benefit subgroup population of adjuvant chemotherapy. <b>Results:</b> After 1∶1 PSM matching,69 patients were obtained in each group. There was no significant difference in baseline data between the two groups (all <i>P</i>>0.05). After PSM,Cox multivariate analysis showed that lymph node metastasis (<i>HR</i>=3.06,95%<i>CI</i>:1.52 to 6.16,<i>P</i>=0.039),width of resection margin (<i>HR</i>=0.56,95%<i>CI</i>:0.32 to 0.99,<i>P</i>=0.044) and adjuvant chemotherapy (<i>HR</i>=0.51,95%<i>CI</i>:0.29 to 0.91,<i>P</i>=0.022) were independent prognostic factors for OS. Kaplan-Meier analysis showed that the median OS time of adjuvant chemotherapy group was significantly longer than that of non-adjuvant chemotherapy group (<i>P</i><0.05). There was no significant difference in RFS time between the adjuvant chemotherapy group and the non-adjuvant chemotherapy group (<i>P</i>>0.05). Subgroup analysis showed that,the OS of female patients,without HBV infection,carcinoembryonic antigen<9.6 μg/L,CA19-9≥200 U/ml,intraoperative bleeding<400 ml,tumor diameter>5 cm,microvascular invasion negative,without lymph node metastasis,and AJCC stage Ⅲ patients could benefit from adjuvant chemotherapy (all <i>P</i><0.05). <b>Conclusion:</b> Adjuvant chemotherapy can prolong the OS of patients with ICC after radical resection,and patients with tumor diameter>5 cm,without lymph node metastasis,AJCC stage Ⅲ,and microvascular invasion negative are more likely to benefit from adjuvant chemotherapy.</p>\",\"PeriodicalId\":23966,\"journal\":{\"name\":\"Zhonghua wai ke za zhi [Chinese journal of surgery]\",\"volume\":\"61 4\",\"pages\":\"305-312\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhonghua wai ke za zhi [Chinese journal of surgery]\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112139-20230106-00010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua wai ke za zhi [Chinese journal of surgery]","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112139-20230106-00010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
研究目的研究根治性切除术后辅助化疗对肝内胆管癌(ICC)患者生存期的影响,并确定可能从中获益的患者。研究方法回顾性收集中国13家医院2011年12月至2017年12月经术后病理确诊的654例ICC患者的临床和病理资料。根据纳入和排除标准,本研究共纳入455例患者,其中69例(15.2%)接受了辅助化疗,386例(84.8%)未接受辅助化疗。其中男性 278 人,女性 177 人,年龄为 59 (16) 岁(M(IQR))(范围:23 至 88 岁)。采用倾向得分匹配法(PSM)来平衡辅助化疗组和非辅助化疗组之间的差异。采用Kaplan-Meier法绘制生存曲线,用Log-rank检验比较两组患者总生存期(OS)和无复发生存期(RFS)的差异。单变量分析用于确定OS的预后因素。然后对预后因素进行多变量Cox比例危险度模型分析,结果为PR:经过 1∶1 PSM 匹配,每组各有 69 名患者。两组基线数据无明显差异(P>0.05)。PSM后,Cox多变量分析显示,淋巴结转移(HR=3.06,95%CI:1.52 to 6.16,P=0.039)、切除边缘宽度(HR=0.56,95%CI:0.32 to 0.99,P=0.044)和辅助化疗(HR=0.51,95%CI:0.29 to 0.91,P=0.022)是OS的独立预后因素。Kaplan-Meier分析显示,辅助化疗组的中位OS时间明显长于非辅助化疗组(PP>0.05)。亚组分析显示,女性患者、无 HBV 感染、癌胚抗原 5 cm、微血管侵犯阴性、无淋巴结转移、AJCC Ⅲ期患者的 OS 可从辅助化疗中获益(均为 PC):肿瘤直径大于5 cm、无淋巴结转移、AJCC分期Ⅲ期、微血管侵犯阴性的ICC患者更容易从辅助化疗中获益。
[Effect of postoperative adjuvant chemotherapy on prognosis of patients with intrahepatic cholangiocarcinoma:a multicenter retrospective study].
Objectives: To examine the influence of adjuvant chemotherapy after radical resection on the survival of patients with intrahepatic cholangiocarcinoma(ICC) and to identify patients who may benefit from it. Methods: The clinical and pathological data of 654 patients with ICC diagnosed by postoperative pathology from December 2011 to December 2017 at 13 hospitals in China were collected retrospectively. According to the inclusion and exclusion criteria,455 patients were included in this study,including 69 patients (15.2%) who received adjuvant chemotherapy and 386 patients (84.8%) who did not receive adjuvant chemotherapy. There were 278 males and 177 females,with age of 59 (16) years (M(IQR))(range:23 to 88 years). Propensity score matching (PSM) method was used to balance the difference between adjuvant chemotherapy group and non-adjuvant chemotherapy group. Kaplan-Meier method was used to plot the survival curve,the Log-rank test was used to compare the difference of overall survival(OS) and recurrence free survival(RFS)between the two groups. Univariate analysis was used to determine prognostic factors for OS. Multivariate Cox proportional hazards models were then performed for prognostic factors with P<0.10 to identify potential independent risk factors. The study population were stratified by included study variables and the AJCC staging system,and a subgroup analysis was performed using the Kaplan-Meier method to explore the potential benefit subgroup population of adjuvant chemotherapy. Results: After 1∶1 PSM matching,69 patients were obtained in each group. There was no significant difference in baseline data between the two groups (all P>0.05). After PSM,Cox multivariate analysis showed that lymph node metastasis (HR=3.06,95%CI:1.52 to 6.16,P=0.039),width of resection margin (HR=0.56,95%CI:0.32 to 0.99,P=0.044) and adjuvant chemotherapy (HR=0.51,95%CI:0.29 to 0.91,P=0.022) were independent prognostic factors for OS. Kaplan-Meier analysis showed that the median OS time of adjuvant chemotherapy group was significantly longer than that of non-adjuvant chemotherapy group (P<0.05). There was no significant difference in RFS time between the adjuvant chemotherapy group and the non-adjuvant chemotherapy group (P>0.05). Subgroup analysis showed that,the OS of female patients,without HBV infection,carcinoembryonic antigen<9.6 μg/L,CA19-9≥200 U/ml,intraoperative bleeding<400 ml,tumor diameter>5 cm,microvascular invasion negative,without lymph node metastasis,and AJCC stage Ⅲ patients could benefit from adjuvant chemotherapy (all P<0.05). Conclusion: Adjuvant chemotherapy can prolong the OS of patients with ICC after radical resection,and patients with tumor diameter>5 cm,without lymph node metastasis,AJCC stage Ⅲ,and microvascular invasion negative are more likely to benefit from adjuvant chemotherapy.